News

FDA approves SAPIEN 3 platform for asymptomatic severe aortic stenosis
The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...
Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients
New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...
U.S. News & World Report2d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis By Lori Solomon HealthDay ReporterMONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...
kpvi3d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
In the EARLY TAVR trial, which informed the approval, patients with asymptomatic severe aortic stenosis were randomly assigned to either TAVR or watchful waiting. During a median follow-up of 3.8 ...
KTEN3d
FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis
MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe ...
Medscape5d
Calcific Aortic Stenosis in the Elderly: A Brief Overview
The increased wall thickness helps normalize wall stress and maintain cardiac output in the normal range. Since there is little hemodynamic consequence to mild and moderate aortic stenosis ...
Yahoo Finance6d
FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients
platform for the treatment of patients with asymptomatic severe aortic stenosis (AS), expanding its use to a broader population. Marking a first approval for a TAVR system’s use in asymptomatic ...